RG1662, a Selective GABAA α5 Receptor Negative Allosteric Modulator, Increases Gamma Power in Young Adults with Down Syndrome. (P6.273)
Citation Manager Formats
Make Comment
See Comments

Abstract
OBJECTIVE: We investigated the effect of RG1662, a GABAAα5 (GABRA5) negative allosteric modulator (NAM), on quantitative EEG (qEEG) in young adults with Down syndrome (DS). BACKGROUND: Intellectual disability associated with DS is believed to relate partly to excessive GABAergic tone. Gamma oscillations are generated by synchronization of pyramidal neurons by fast-spiking GABAergic interneurons. RG1662 is a highly selective NAM of GABA-A receptors containing the GABRA5 subunit, a target for enhancement of cognition. DESIGN/METHODS: In a randomized, double blind, placebo-controlled, multiple ascending dose study in young adults with DS aged 18-30 years, subjects received placebo, 80, 160, or 370 mg BID of RG1662 for 5 weeks (n = 8 per group). EEG recordings were obtained at baseline, day 1, and day 10. We performed a power band analysis and fit an MMRM model to the data. A classifier was also built to separate EEG features in people with DS from matched typically developing (TD) controls using PCA and an SVM algorithm. In addition, extracellular recordings in brain slices from WT and GABRA5 KO mice were used to explore GABRA5-dependency of the effects. RESULTS: There were no EEG signs of epileptiform abnormality. We observed statistically significant (p < 0.001) dose-dependent increases in gamma power after 10 days of dosing with RG1662. We were able to construct a multivariate DS index with good sensitivity and specificity (ROC AUC = 0.87). We observed a dose-dependent lowering of the DS index. Also, RG1662 modulated carbachol-induced gamma oscillations in hippocampal brain slices of WT mice, but not GABRA5 KO mice. CONCLUSIONS: GABRA5 inhibition results in clear qEEG effects in young adults with DS and may be a useful pharmacodynamic biomarker for this class of compounds. Rodent experiments suggest these effects are GABRA5-dependent. We are investigating EEG data from TD controls given multiple ascending doses of RG1662.
Disclosure: Dr. Bolognani has received personal compensation for activities with Roche as an employee. Dr. Squassante has received personal compensation for activities with Roche Diagnostics Corporation as an employee. Dr. Liogier d'Ardhuy has received personal compensation for activities with Roche Diagnostics Corporation as an employee. Dr. Hernandez has received personal compensation for activities with Roche Diagnostics Corporation as an employee. Dr. Knoflach has received personal compensation for activities with Roche Diagnostics Corporation as an employee. Dr. Baldinotti has received personal compensation for activities with Roche as an employee. Dr. Noeldeke has received personal compensation for activities with Roche Diagnostics Corporation as an employee. Dr. Wandel has received personal compensation for activities with Roche Diagnostics Corporation as an employee. Dr. Nave has received personal compensation for activities with Roche Diagnostics Corporation as an employee. Dr. Khwaja has received personal compensation for activities with Roche Diagnostics Corporation as an employee.
Thursday, April 23 2015, 7:30 am-12:00 pm
- Copyright © 2015 by AAN Enterprises, Inc.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Jessica Ailani and Dr. Ailna Masters-Israilov
► Watch
Related Articles
- No related articles found.